RCS - MaxCyte, Inc. - Upcoming Investor Conferences

MaxCyteAnnouncement

31/10/2024 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241031:nRSe4096Ka&default-theme=true

RNS Number : 4096K  MaxCyte, Inc.  31 October 2024

MaxCyte to Participate in Two Upcoming Investor Conferences

 

 

Rockville, MD, Oct. 31, 2024 - MaxCyte, Inc.
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2Ojk2MGQ6M2Q0Y2M0Y2IyMzI3OGExYjcwZmZiN2YxMzNhMDYzYmY2YzNiMDBiMzZlMDQwNGVmM2JmOTc2M2U1NDMxYTc2YzpwOkY6Rg)
, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell-based therapeutics, today
announced Company management will participate at two upcoming investor
conferences.

 

·    Stifel 2024 Healthcare Conference

Fireside Chat on Monday, November 18(th) at 10:55 AM ET

 

·    Stephens Annual Investment Conference

Fireside Chat on Tuesday, November 19(th) at 3:00 PM CT

 

A live and archived webcast of the event will be available on the "Events"
section of the MaxCyte investor relations website at
https://investors.maxcyte.com/ (https://investors.maxcyte.com/) .

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmE1MjQ6ZjkwYTM4NTFkYzFjZTE4MDc3MzEzMDUxMzdhY2YwMjI4NmExYzRmM2IyYTQ4MGRkNjJhMTZiYmUyNzZkMWE4NDpwOlQ6Rg)
and follow us on X
(https://protect.checkpoint.com/v2/___https:/twitter.com/MaxCyte_info___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmNlODY6NGQ3NmQ0ODY5ZWMwZGM2ZWY3YWE0YzdmMzljY2UyODM4ZTExMGI5OWRjODhlYjk5NmI3ZjcyZTNlNTIxZGE4ZDpwOlQ6Rg)
and LinkedIn
(https://protect.checkpoint.com/v2/___https:/www.linkedin.com/company/maxcyte-inc-/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmE5Yjg6ODI4ODYyMDRkZDU5YTY0MjUyMzY1NGQwMjczZDA2NTM5YTI1MDcxM2Y4NjgyNWUxODM5YTcxMTc4ZDJkYmRiMDpwOlQ6Rg)
.

 

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Science

Jordan Vines+1 540-629-3137

jvines@spectrumscience.com (mailto:jvines@spectrumscience.com)

 

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@icrhealthcare.com (mailto:maxcyte@icrhealthcare.com)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKDBKCBDKCKN